Lanthio Pharma expands management team

20-Sep-2016 - Netherlands

The Dutch biopharmaceutical company Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG, announced the appointment of Axel Mescheder, M.D. as Chief Medical Officer (CMO).

Dr. Heinz Schwer, Chief Executive Officer of Lanthio Pharma, commented: "We are very pleased to welcome Axel Mescheder at Lanthio Pharma where he will take a key role in the Company's management. We got to know him as an excellent clinical physician and experienced R&D manager and we are sure that he will further strengthen and complement our management team. Axel's main focus will be the development of Lanthio Pharma's lanthipeptide portfolio, in particular the preparation and subsequent execution of the clinical development of MOR107."

Dr. Mescheder has more than 20 years of experience in R&D management positions in the pharmaceutical and biotechnology industry. He has demonstrated the ability to successfully develop, implement and drive clinical development programs and has a track record of advancing a number of compounds through the various clinical phases that lead to product registration or label extensions, either in Europe or in the US. He joins Lanthio Pharma from Medpace GmbH, Munich/Germany, where he acted as Vice President Medical & Regulatory Affairs Europe. Prior to that, he held the positions of Chief Medical and Development Officer at TopoTarget A/S, Copenhagen/Denmark, and Medigene AG, Munich/Germany. From 2001 to 2003 he worked at MorphoSys AG as a Medical Director. Prior to that, Dr. Mescheder held various management positions in research and development at Genetics Institute/Wyeth-Ayerst Research (Pfizer), Centeon (CSL Behring) and Hoffmann-La Roche.

https://www.bionity.com/en/news/159784/lanthio-pharma-expands-management-team.html